Navigation Links
Elcelyx Therapeutics' NewMet for Type 2 Diabetes Meets Primary Endpoint in Phase 2b Study
Date:9/4/2013

SAN DIEGO, Sept. 4, 2013 /PRNewswire/ -- Elcelyx Therapeutics announced today that NewMet™, the delayed-release formulation of generic metformin for the treatment of patients with Type 2 diabetes, met its primary study endpoint with statistically significant reductions in fasting plasma glucose at four weeks of treatment compared to placebo. 

The results from the randomized, 240-patient, multicenter U.S. Phase 2b trial confirm previous studies that showed NewMet reduced fasting plasma glucose to a similar extent as generic metformin but at plasma exposure levels previously shown to be as much as 65% lower than comparable doses of generic metformin.

The double-blind, dose-finding trial evaluated NewMet once-daily doses of 1,000, 800 and 600 milligrams compared to placebo. There were also two comparator arms with Glucophage XR dosed once-daily at 1,000 and 2,000 milligrams. Secondary endpoints through 12 weeks include changes in fasting plasma glucose, hemoglobin A1c, body weight and measures of safety and tolerability. Twelve-week results are expected in late October.

The results at four weeks provide confirmation that the primary site of metformin activity is the lower bowel and not the circulation.  The reduced systemic absorption of NewMet indicates that it may be an appropriate treatment for Type 2 diabetes patients who have renal impairment and are contraindicated for metformin use due to the risk of lactic acidosis, a life-threatening condition that can result from metformin build-up in the blood.

About Elcelyx Therapeutics, Inc.

Elcelyx Therapeutics is developing pharmaceutical product candidate NewMet™ for use by Type 2 diabetes patients who have difficulty tolerating generic metformin or are contraindicated for its use. NewMet presents a near-term, blockbuster commercial opportunity. Elcelyx is based in San Diego, CA. For more information, visit www.Elcelyx.com.

 

 


'/>"/>
SOURCE Elcelyx Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Elcelyx Therapeutics Reports Positive Data for NewMet in Type 2 Diabetes at 2013 American Diabetes Association Scientific Sessions
2. Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes
3. Elcelyx Therapeutics Completes $20 Million Series C Financing to Advance NewMet and Lovidia
4. Elcelyx Therapeutics Names Mark Wiggins Senior Vice President of Business Development, Ginger Graham to Board of Directors
5. Aratana Therapeutics Drives Awareness of Pet Therapeutic Opportunity During "CVC Week" in Kansas City
6. Mast Therapeutics To Present At The Rodman & Renshaw 15th Annual Healthcare Conference On September 10
7. PTC Therapeutics to Present at Upcoming Investor Conferences
8. Aratana Therapeutics to Host Pet Therapeutics Primer and Product Update Event
9. Carolus Therapeutics and The Alpha-1 Project Collaborate to Validate CT-2009 Target as Important in Human Disease
10. Echo Therapeutics Announces Management Changes
11. aTyr Pharma Awarded Two Patents from USPTO to Support Development of New Therapeutics Based on Physiocrine Biology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... FinancialBuzz.com News Commentary ... is strongly contributing to job creation. A recent report ... for the cannabis industry, projects that by 2020, the ... million jobs for American workers. The legal cannabis market ... is projected to grow at a compound annual growth ...
(Date:3/22/2017)... LUND, Sweden , March 22, 2017 ... Saleh and Mr. Ed Tumaian , two global executive ... Tumaian will be joining the Operational Leadership Team and will report ... ... Saleh comes to TFS with 10 years of medical and ...
(Date:3/22/2017)... March 22, 2017 EMD Serono, the biopharmaceutical business ... the U.S. and Canada , today announced ... poster presentation session at the 65 th Annual Pacific ... California on March 24 th .   ... real-world database collected from July 2009 to December 2015 containing ...
Breaking Medicine Technology:
(Date:3/22/2017)... (PRWEB) , ... March 22, 2017 , ... ... that serves communities throughout north Jersey and the New York metropolitan region, is ... provide regional support for homeless families. , At present, more than two and ...
(Date:3/22/2017)... ... March 22, 2017 , ... The Vanderbeck Agency, a Long ... Nassau County region, is embarking on a combined charity effort with the Great Neck ... the last 25 years, the Great Neck Breast Cancer Coalition has worked to support ...
(Date:3/22/2017)... City, OK (PRWEB) , ... March 22, 2017 ... ... offering insurance and financial planning services to regional families and business owners, is ... meaningful support to young people in the area. , A growing number of ...
(Date:3/22/2017)... ... 22, 2017 , ... The Zabbia Insurance Agency, a Long ... business owners in the greater Nassau County area, is embarking on a cancer ... 3 minutes, someone in America is diagnosed with blood cancer. Every 9 minutes, ...
(Date:3/22/2017)... ... March 22, 2017 , ... Martin J. Mitchell Insurance, ... to communities throughout central Ohio, is initiating a charity drive to raise support ... of Defense and the Veteran's Brain Injury Center conclude that more than one ...
Breaking Medicine News(10 mins):